Key result
Macular carotenoid supplementation significantly reduces inflammatory cytokines and oxidized LDL versus placebo.
RCT
Double-blind
randomly allocated
Answers are grounded in this paper and cite their sources.
BACKGROUND AND AIMS: Systemic inflammation and oxidation are primary contributors to the development of atherosclerosis. Oxidation of low-density lipoprotein (LDL) particles within the vascular endothelium has been hypothesized to be an initial step in the formation of atherosclerotic plaques, with inflammatory cytokines serving as the signaling mechanism for concomitant macrophage activation. Supplementation with the antioxidative macular xanthophylls (lutein [L], zeaxanthin [Z], and meso-zeaxanthin [MZ]) has been shown to aid in the reduction of inflammatory physiologic responses; therefore, we hypothesized that in our study population, supplementation with these xanthophylls would facilitate a systemic reduction in markers of inflammation and cardiovascular lipid oxidation. METHODS AND RESULTS: In this double-blind placebo-controlled supplementation study, participants were randomly allocated to receive the active intervention containing L (10 mg) + MZ (10 mg) + Z (2 mg) or placebo (containing sunflower oil). Serum concentrations of carotenoids (assessed by HPLC), inflammatory cytokines (IL-6, IL-1β, TNF-α) and oxidized LDL (OxLDL; by solid-phase sandwich ELISA) were measured at baseline and at 6-months. Results showed that over the supplementation period, compared to placebo, the active group demonstrated statistically significant increases in serum concentrations of L, Z, & MZ (p < 0.05), reductions in inflammatory cytokines IL-1β (p < 0.001) and TNF-α (p = 0.003), as well as a corresponding reduction in serum OxLDL (p = 0.009). CONCLUSIONS: Our data show that L, Z, & MZ supplementation results in decreased serum IL-1β, TNF-α, and OxLDL. This suggests that these carotenoids are acting systemically to attenuate oxidative lipid products and inflammation, thus reducing their contribution to atherosclerotic plaque formation.
No takes yet. Share an insight, caveat, or question.
Stringham et al. (2024) reported an RCT. Lutein (L), zeaxanthin (Z), and meso-zeaxanthin (MZ) vs. Placebo was evaluated on Serum concentrations of carotenoids, inflammatory cytokines (IL-6, IL-1β, TNF-α) and oxidized LDL (p=<0.001). Supplementation with lutein, zeaxanthin, and meso-zeaxanthin for 6 months reduced serum IL-1β, TNF-α, and oxidized LDL compared to placebo.
Synapse has enriched 10 related papers. Consider them for comparative context: